Long-term debt · 2011–2023
Exact Sciences long-term debt
$50.0M+110.5% · FY2023
Exact Sciences (EXAS) reported $50.0M in long-term debt for fiscal 2023, +110.5% year on year.
| Fiscal year | Long-term debt | Change | Filing |
|---|---|---|---|
| FY20232023-12-31 | $50.0M | +110.5% | Open → |
| FY20202020-12-31 | $23.8M | −1.2% | Open → |
| FY20192019-12-31 | $24.0M | −1.9% | Open → |
| FY20182018-12-31 | $24.5M | +473.8% | Open → |
| FY20172017-12-31 | $4.3M | −7.9% | Open → |
| FY20162016-12-31 | $4.6M | −3.3% | Open → |
| FY20152015-12-31 | $4.8M | +378.9% | Open → |
| FY20142014-12-31 | $1.0M | 0.0% | Open → |
| FY20132013-12-31 | $1.0M | 0.0% | Open → |
| FY20122012-12-31 | $1.0M | 0.0% | Open → |
| FY20112011-12-31 | $1.0M | — | Open → |
Long-term debt — Long-term debt is borrowing due more than a year out. A large figure is normal for capital-intensive businesses and says nothing on its own about financial health.
Every row links to its own SEC filing · Fiscal year 2025 · Data as of September 25, 2026 · 2011–2023 compound annual growth +38.5%
Long-term debt at companies of similar size
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Exact Sciences long-term debt |url=https://companiesranked.com/en/company/exact-sciences/long-term-debt |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Exact Sciences long-term debt. CompaniesRanked. https://companiesranked.com/en/company/exact-sciences/long-term-debtBibTeX
@misc{companiesranked-en-company-exact-sciences-long-term-debt-2026,
author = {{CompaniesRanked}},
title = {{Exact Sciences long-term debt}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/exact-sciences/long-term-debt}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.